Double-Drug attack on lung cancer shows promise in early trial
NCT ID NCT03122717
First seen Nov 12, 2025 · Last updated Jun 12, 2026 · Updated 29 times
Summary
This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer. About 48 participants who have not received prior EGFR inhibitor treatment will take both drugs for up to 6 months. The main goal is to see how many can stay on the combination therapy without stopping due to side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.